The strong efficacy and safety data combined with FDA alignment on Phase 3 design significantly de-risk ELVN-001. Traders should watch for initiation of the ENABLE-2 trial in H2 2026 and any additional data presentations. The stock may re-rate as the program transitions to pivotal development.
Price Chart
Executive Summary
Enliven Therapeutics reported updated positive Phase 1 data for ELVN-001 in CML, showing a 61% overall MMR and 48% MMR achievement by 24 weeks in the 80 mg QD cohort, with a favorable safety profile (6% discontinuation rate). The company also announced FDA alignment on the 80 mg QD dose and the 2L+ patient population for the planned Phase 3 ENABLE-2 trial, expected to initiate in H2 2026. This is a significant clinical and regulatory milestone that de-risks the program and supports a clear path to pivotal development.
Key Facts
- 61% overall MMR and 48% MMR achievement by 24 weeks in the 80 mg QD Phase 1b cohort (n=28 evaluable).
- 67% overall MMR and 55% MMR achievement by 24 weeks in all Phase 1b patients with 1-2 prior TKIs.
- FDA alignment on 80 mg QD as the recommended Phase 3 dose and on the 2L+ patient population for ENABLE-2.
- ENABLE-2 pivotal trial expected to initiate in the second half of 2026.
- Favorable safety profile: 6% discontinuation rate due to AEs; Grade 3 TEAEs in 24% of patients at 80 mg QD.
- 161 patients enrolled as of March 10, 2026 cutoff; 76% remain on study with median treatment duration of 35 weeks.
- Prior asciminib exposure did not meaningfully impact response rates.
Financial Impact
No financial data provided in the filing. The clinical milestone supports potential future revenue from ELVN-001 if approved, but no revenue or earnings figures are disclosed.
Risk Factors
- Phase 3 trial may fail to replicate Phase 1 results in a larger, randomized setting.
- Competition from approved TKIs (e.g., asciminib, ponatinib) and other pipeline candidates.
- Regulatory delays or changes in trial design requirements from the FDA.
- Enliven is a clinical-stage company with no approved products or revenue, dependent on capital markets for funding.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-266731 |
| Document: d202685dex991.htm | 0001193125-26-266731 |
| Document: 0001193125-26-266731-index-headers.html | 0001193125-26-266731 |
| Document: 0001193125-26-266731-index.html | 0001193125-26-266731 |
| Document: 0001193125-26-266731.txt | 0001193125-26-266731 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 21, 2026 4d ago | Insider Cluster | $41.93 | awaiting T+5 | — | $41.49 (−1.05%) |
Oct 19, 2026 7d ago | 144 | $41.25 | awaiting T+5 | — | $41.49 (+0.58%) |
Oct 16, 2026 10d ago | 3 | $38.70 $41.49 | ▲ +7.21% | ▲ +7.35% | $41.49 (+7.21%) |
Oct 14, 2026 12d ago | 8-K | $39.33 $41.93 | ▲ +6.61% | ▲ +7.63% | $41.49 (+5.49%) |
Sep 21, 2026 5w ago | Insider Cluster | $48.19 $46.51 | ▼ −3.49% | ▼ −2.30% | $41.49 (−13.90%) |
Sep 4, 2026 7w ago | 144 | $59.32 $54.43 | ▼ −8.24% | ▼ −7.03% | $41.49 (−30.06%) |
Aug 19, 2026 9w ago | Insider Cluster | $58.97 $60.50 | ▲ +2.59% | ▲ +1.48% | $41.49 (−29.64%) |
Aug 9, 2026 11w ago | Institutional Cluster | $59.42 $59.54 | ▲ +0.19% | ▲ +0.24% | $41.49 (−30.18%) |
Jul 21, 2026 13w ago | Insider Cluster | $52.85 $52.97 | ▲ +0.23% | ▲ +2.63% | $41.49 (−21.49%) |
Jun 22, 2026 17w ago | 144 | $48.60 $50.85 | ▲ +4.63% | ▲ +3.62% | $41.49 (−14.63%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers